United Kingdom: Positive Results for HIV Drug Study
July 16, 2012
A once-daily triple-drug HIV regimen containing an experimental integrase inhibitor performed better in suppressing the virus than Atripla in a Phase III trial, developers of the new drug say. The trial pitted dolutegravir in combination with two older HIV drugs against the three-drug Atripla.
Results from the SINGLE trial found 88 percent of patients taking the dolutegravir-based regimen achieved undetectable virus at 48 weeks, compared with 81 percent for Atripla patients. Dolutegravir is being developed by Japanese partner Shionogi & Co. and ViiV Healthcare, a partnership of UK-based GlaxoSmithKline and US-based Pfizer.
Complete trial results will be presented at an upcoming scientific meeting. In April, the first set of study results showed dolutegravir was as effective as twice-daily Isentress. Four Phase III studies due for reporting this year are designed to accompany regulatory filings in support of the drug.
Dolutegravir's low-milligram dosing could make it easier to include in a fixed-dose combination pill, and there could be fewer side effects because a booster is not required.
Wall Street Journal
07.11.2012; Sten Stovall
Studies on Pipeline ARVs: Quad, Elvitegravir/Cobicistat, Cobicistat, GSK1265744, BMS986001 Dolutegravir, GSK-1265744, Long-Acting Formulations (Monthly Injections): Rilpivirine-LA, Raltegravir and Patient Views
This article was provided by CDC National Prevention Information Network. It is a part of the publication CDC HIV/Hepatitis/STD/TB Prevention News Update.
Add Your Comment:
(Please note: Your name and comment will be public, and may even show up in
Internet search results. Be careful when providing personal information! Before
adding your comment, please read TheBody.com's Comment Policy.)